Therapy of type 1 diabetes with CD4+CD25highCD127-regulatory T cells prolongs survival of pancreatic islets 鈥?Results of one year follow-up
详细信息 查看全文
- 作者：Natalia Marek-Trzonkowskaa ; 1 ; Ma艂gorzata My艣liwiecb ; 1 ; Anita Dobyszukc ; Marcelina Grabowskac ; Ilona Derkowskab ; Jolanta Ju艣ci艅skad ; Rados艂aw Owczuke ; Agnieszka Szadkowskaf ; Piotr Witkowskig ; Wojciech M艂ynarskif ; Przemys艂awa Jarosz-Choboth ; Artur Bossowskii ; Janusz Sieberta ; Piotr Trzonkowskic ; ptrzon@gumed.edu.pl" class="auth_mail
- 关键词：anti-GAD ; glutamic acid decarboxylase autoantibodies ; anti-IA2 ; tyrosine phosphatase-related islet antigen 2 autoantibodies ; b.w ; body weight ; cGMP ; current good manufacturing practice ; DDI ; daily dose of insulin ; DM1 ; type 1 diabetes mellitus ; GvHD ; graft versus host disease ; HEPA ; high-efficiency particulate absorption ; IAA ; insulin autoantibodies ; ICA ; islet cell autoantibodies ; IFN纬 ; interferon 纬 ; Tregs ; T regulatory cells ; HBV ; hepatitis B virus
- 刊名：Clinical Immunology
- 出版年：July 2014
- 年：2014
- 卷：153
- 期：1
- 页码：23-30
- 全文大小：1102 K
文摘
- bel">•
This study shows first-in-man treatment of type 1 diabetes with T regulatory cells.
- bel">•
It has been found that repetitive administration of Tregs in DM1 children is safe.
- bel">•
The administration of Tregs prolonged survival of 尾 cells in DM1 patients.